Introduction {#S1}
============

Multiple system atrophy (MSA) is a progressive neurodegenerative disease characterized by the clinical triad of parkinsonism, cerebellar ataxia and autonomic dysfunction ([@B22]; [@B13]) and pathologically by abnormal α-synuclein deposition in oligodendrocytes, called glial cytoplasmic inclusions (GCIs) ([@B14]; [@B19]; [@B7]). The sequence of pathological events in MSA is recognized as oligodendrocyte dysfunction first, followed by neurodegeneration and loss of neurons ([@B1]; [@B18]; [@B10]). While the general consensus is that MSA is a highly sporadic disease, emerging evidence has suggested rare genetic variants increase susceptibility, although this appears to be dependent on the geographical distribution of sample patients ([@B17]; [@B8]; [@B21]; [@B12]).

One such gene is COQ2 ([@B12]). COQ2 encodes a biosynthetic enzyme (coenzyme-Q2-polyprenyltransferase) in the production of coenzyme Q~10~, which is required for the production of ATP ([@B15]). Coenzyme Q~10~ is reduced in MSA and not in other parkinsonian disorders, although there is considerable variation in the amount of reduction noted (3--5% versus 40%) ([@B3]; [@B16]) and the downstream deficits observed in electron chain transport enzymes ([@B3]; [@B16]; [@B6]). Reductions in coenzyme Q~10~ are likely be due to variations in other biosynthetic enzymes for coenzyme Q~10~ production, as reductions in PDSS1 (the initiating enzyme) and COQ5 have been identified in MSA ([@B3]; [@B16]). Interestingly, the level of COQ2 protein was not altered in MSA cerebellum in Tris--HCl buffer ([@B3]), a tissue fraction unlikely to contain mitochondrial proteins in abundance. To date, whether any of the changes to this pathway in MSA affect ATP production remains unknown. In this study, we assessed whether the levels of ATP are perturbed in MSA and reassessed whether biosynthetic enzymes for coenzyme Q~10~, including COQ2, are involved.

Materials and Methods {#S2}
=====================

Human Brain Tissues {#S2.SS1}
-------------------

Human brain tissues were obtained from the Sydney Brain Bank and NSW Tissue Resource Centre. Ethics approval was from the University of New South Wales Human Research Ethics Committee. Frozen brain tissues from 8 MSA cases and 10 controls were used in this study. MSA brains were clinically and pathologically diagnosed using international diagnostic criteria ([@B23]). Controls were free of significant neuropathology. The mean age of MSA cases and controls were 67.7 ± 7.5 and 77.4 ± 8.1 years, respectively. The make up of gender (male/female) was 7/1 and 7/3, respectively. Approximately 50 mg of brain tissue from anatomically specified regions were collected using a 3-mm stainless steel biopsy needle from frozen brain slices (dissected on a bed of dry-ice).

Detection of GCIs {#S2.SS2}
-----------------

Formalin-fixed coronal blocks of white matter underlying motor cortex were paraffin-embedded, cut at 10 μm on a microtome, and mounted on 3-aminopropyltriethoxysilane-coated slides. Following pretreatment with 99% formic acid for 3 min, immunoperoxidase staining was performed using antibodies to α-synuclein (mouse mAb42, BD Transduction Labs, United States; diluted 1:100) and an avidin-biotin-peroxidase detection system (Vector Laboratories, Burlingame, CA, United States). Sections were counterstained with 0.5% cresyl violet to identify cell constituents. Labeled sections were evaluated and photographed using an Olympus BX51 fluorescence microscope fitted with specific filter systems and a computerized image analysis system (SPOT camera, Image Pro Plus software).

ATP Assay {#S2.SS3}
---------

Colorimetric ATP assay was carried out following the manufacturer's protocol (Abcam, Melbourne, VIC, Australia). Briefly, 10 mg of pulverized frozen tissues were homogenized in 100 μl of ATP assay buffer using a motorized pestle, centrifuged at 13,000 *g* for 5 min at 4°C, and the supernatant collected for analysis. The samples and the standards were added to a 96-well plate containing the ATP Probe reagents and incubated at room temperature in the dark for 30 min. The plate was read using a microplate reader at 570 nm and ATP levels normalized to protein concentration.

RNA Isolation, Reverse Transcription and Quantitative PCR {#S2.SS4}
---------------------------------------------------------

RNA was isolated using TRI Reagent (Sigma, Castle Hill, NSW, Australia) following the manufacturer's protocol from control (*n* = 10) and MSA (*n* = 8) tissues. RNA integrity was assessed with high resolution capillary electrophoresis (Agilent Technologies) and only RNA with RNA Integrity Number value \>6.0 was used in the cDNA synthesis. All procedures were carried out using RNase-free reagents and consumables. Five micrograms of RNA was reverse transcribed into cDNA using Moloney-murine leukemia virus reverse transcriptase and random primers (Promega, Annandale, NSW, Australia) in a 20 μl reaction volume. cDNA was used as a template in the quantitative real-time PCR (qPCR) assay, which was carried out using a Mastercycler ep realplex S (Eppendorf) and the fluorescent dye SYBR Green (Bio-Rad), following the manufacturer's protocol. Briefly, each reaction (20 μl) contained 1× RealMasterMix, 1× SYBR green, 5 pmoles of primers and 1 μl of template. Amplification was carried out with 40 cycles of 94°C for 15 sec and 60°C for 1 min. Gene expression was normalized to the geometric mean of three housekeeper genes, β-actin, GAPDH and glucuronidase-β. The level of expression was calculated using the comparative threshold cycle (Ct) value method using the formula 2^--ΔΔCt^ (where ΔΔCt = ΔCt sample -- ΔCt reference).

Statistical Analysis {#S2.SS5}
--------------------

MSA and control tissue samples examined were *n* = 8 and *n* = 10, respectively. Data presented are expressed as mean [+]{.ul}SE shown by the error bars. Statistical significance was analyzed using the Student's *t*-test with a *p* \< 0.05 considered significant.

Results and Discussion {#S3}
======================

Decreased ATP Levels in MSA Brain {#S3.SS1}
---------------------------------

Coenzyme Q~10~ is responsible for ATP production ([Figure 1A](#F1){ref-type="fig"}). Here, we analyzed brain tissues from eight clinically and pathologically characterized MSA cases ([@B23]) and ten controls without significant neuropathology. Frozen tissue from four specific brain regions were analyzed -- disease-affected degenerating gray matter (cerebellum and putamen), disease-affected without significant degeneration (white matter underlying motor cortex) and an unaffected region of the brain (visual cortex). Firstly, we confirmed, by immunohistochemistry, that GCIs were present in the disease-affected regions of MSA brain ([Figure 1B](#F1){ref-type="fig"}). We then measured ATP levels and found that they were significantly decreased in the cerebellum and motor cortex with a non-significant decrease in the putamen, and no differences in the visual cortex ([Figure 1C](#F1){ref-type="fig"}).

![ATP levels in MSA and control brains. **(A)** The biosynthetic pathway of coenzyme Q~10~ and its downstream markers, ATP and ABCA8. **(B)** Immunohistochemistry of cells in the white matter underlying motor cortex using α-synuclein antibody and Nissl staining. **(C)** ATP levels in disease-affected regions (cerebellum, white matter underlying motor cortex and putamen) and disease-unaffected region (visual cortex) of MSA (*n* = 8) and control (*n* = 10) brains. Data represent mean and SE as error bars, ^∗^*p* \< 0.05.](fnins-13-01187-g001){#F1}

*In vivo* magnetic spectroscopic imaging evaluation of ATP levels in the basal ganglia in early MSA patients also showed no significant reduction ([@B20]), but our results suggest that ATP levels are affected in the cerebellar pathways, at least over the disease course. This is consistent with the reliable reduction in coenzyme Q~10~ measured in cerebellar samples, as compared with striatal samples ([@B3]; [@B16]). The cerebellum has the highest density of ATP binding sites in the brain ([@B2]), using ATP to upregulate synaptic activity ([@B5]). Of note, lower ATP levels are found in the human cerebellum compared with other brain regions ([@B9]) and our data suggests a further reduction in MSA similar to the previously described 30--40% reduction in enzymatic activity in the electron transport chain in MSA ([@B3]; [@B16]).

Decreased COQ2 and COQ7 Expression in MSA Brain {#S3.SS2}
-----------------------------------------------

To account for the decreased ATP levels in MSA, we then analyzed the expression of COQ2 in the same four tissues. COQ2 plays a pivotal role in the biosynthesis of coenzyme Q~10~, combining two essential components, para-hydroxybenzoate and decaprenyl-pyrophosphate ([Figure 1A](#F1){ref-type="fig"}). We found that COQ2 mRNA levels were significantly decreased in MSA compared to controls in all three disease-affected regions and unaltered in the visual cortex ([Figure 2A](#F2){ref-type="fig"}). In addition, we analyzed the expression of PDSS1, COQ5, and COQ7 mRNAs in the cerebellum. We found that COQ7 mRNA levels were significantly decreased in MSA compared to controls, whereas PDSS1 and COQ5 mRNA levels were unchanged ([Figure 2B](#F2){ref-type="fig"}). While this contrasts with previous data using the most soluble protein fraction of MSA cerebellar tissue ([@B3]; [@B16]), our data show significantly reduced expression of COQ2 and COQ7 mRNAs and not PDSS1 and COQ5 mRNAs in this region in MSA. The loss of soluble PDSS1 and COQ5 protein described previously ([@B3]; [@B16]) may reflect a compensatory redistribution of these proteins to mitochondrial tissue fractions. Importantly, we found that COQ2 (Spearman's correlation = 0.489; *P* \< 0.05) and COQ7 (Spearman's correlation = 0.555; *P* \< 0.05) expression levels were correlated to ATP levels in the cerebellum, supporting a relationship between reductions in COQ2 and COQ7 mRNA levels and ATP levels in MSA tissue. Furthermore, COQ2 and COQ7 expression levels were correlated to each other (Spearman's correlation = 0.535; *P* \< 0.05).

![Expression of the main biosynthetic enzymes in coenzyme Q~10~ production. COQ2 mRNA expression in disease-affected regions cerebellum **(A)**, white matter underlying motor cortex **(B)** and putamen **(C)** and disease-unaffected region visual cortex **(D)** of MSA and control brains. **(E)** PDSS1, COQ5 and COQ7 mRNA expression in the cerebellum of MSA and control brains. **(F)** ABCA8 mRNA expression in the cerebellum of MSA and control brains. Data represent mean of MSA (*n* = 8) and control (*n* = 10) brains, and SE as error bars, ^∗^*p* \< 0.05.](fnins-13-01187-g002){#F2}

To further investigate the impact of decreased COQ2/COQ7 mRNA levels on ATP production in MSA, we measured the expression of the ATP-dependent gene ABCA8 (ATP Binding Cassette A8), which is implicated in oligodendrocyte lipid dysregulation in MSA pathogenesis ([@B4]; [@B11]). We found that ABCA8 mRNA expression was significantly upregulated in MSA cerebellum compared to controls ([Figure 2C](#F2){ref-type="fig"}) as a feedback response to the decreased ATP levels in MSA brain. When put together, these data suggest that the biosynthetic enzymes involved in the coenzyme Q~10~ production are specifically altered in disease-affected regions of MSA brain, resulting in the reduction of coenzyme Q~10~ and ATP levels, and a subsequent alteration in ATP-dependent activity. These results support further investigation into the role of biosynthetic enzymes in coenzyme Q~10~ production in MSA pathogenesis.
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